Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Biogen Inc. BIIB

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug...

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:Biogen Sees Two Long-Time Directors Announce Retirement

A little fresh blood in management is good.  rate and reply

Biogen Sees Two Long-Time Directors Announce Retirement

Biogen Inc appears to be facing issues related to its executive team. The firm this morning indicated that two long time directors of the company will be retiring from their positions. The retirements...read more

Who is FormTex?

Newly acquired by Good Natured for USD $4.8M, FormTex generated unaudited revenue of USD $5.1M for the trailing twelve months ended February 28, 2022, and an unaudited gross margin rate of approximately 42% in FY2021. Through this acquisition, GDNP now has strategic access to Texas and the Southern US. and will be able to leverage Houston-based manufacturing, importing, warehousing, and logistics to service the southeastern U.S. market, including Florida, Georgia, and North Carolina. ...read more

Outrageous that this was ever approved.

They fail to mention the brain lesions, edema, and bleeding that this drug causes.  They fail to mention that the average AD patient will be able to afford ongoing treatment of this drug due to...read more

$BIIB THE PATH AHEAD ISN’T EASY!

BIOGEN SCORES A BIG WIN FOR ADUHELM™, BUT THE PATH AHEAD ISN’T EASY!  rate and reply